No combination trials found
No published clinical study of the BPC-157 and TB-500 combination was identified on PubMed. Available material is preclinical work on each component or user reports.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →
A combination of two tissue repair peptides. BPC-157 contributes localised healing and angiogenesis while TB-500 contributes systemic anti-inflammatory action and tissue remodelling. No published clinical study has tested the pairing itself in people.
Vendor listings
Show prices as
79 listings · BPC-157 + TB-500
In stock10mgseen 6d ago
In stock10mgseen 7d ago
In stock10mgseen 4d ago
In stock10mgseen 5d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
In stock20mgseen 6d ago
In stock10mgseen 3d ago
In stock10mgseen 3d ago
In stock10mgseen 3d ago
In stock20mgseen 4d ago
In stock20mgseen 7d ago
In stock10mgseen 6d ago
In stock10mgseen 6d ago
In stock10mgseen 6d ago
In stock10mgseen 5d ago
In stock10mgseen 7d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock20mgseen 4d ago
Overview
A combination of two tissue repair peptides. BPC-157 contributes localised healing and angiogenesis while TB-500 contributes systemic anti-inflammatory action and tissue remodelling. No published clinical study has tested the pairing itself in people.
What the research reports
Outcomes described across the published BPC-157 + TB-500 literature and ongoing study. Read each as research context, not a promised result.
Combined repair mechanisms
Pairs localised angiogenic action with systemic actin regulation, which is the stated rationale for stacking the two peptides in research. Reported in research settings.
Recovery support research
Popular in athletic recovery contexts for tendon, muscle and joint work, though the combination itself has no published clinical trial. Reported in research settings.
Localised and systemic reach
BPC-157 is often injected near the injury while TB-500 is dosed systemically, giving the blend two different routes of action. Reported in research settings.
Convenience of one protocol
Combining both into a single weekly schedule reduces the number of separate protocols to track during a research period. Reported in research settings.
Component level study evidence
Each peptide has its own preclinical record, so the blend inherits the evidence of its parts rather than adding evidence of its own. Reported in research settings.
Dosage and protocol
Combination protocols pair BPC-157 at 250 to 500 mcg per day with TB-500 at 2 to 5 mg twice weekly, both given subcutaneously, typically across 4 to 8 weeks of research protocol time.
Clinical evidence
The published record, labeled by strength so you can see what is settled and what is still emerging.
No published clinical study of the BPC-157 and TB-500 combination was identified on PubMed. Available material is preclinical work on each component or user reports.
SourceThe nearest human data is a 2021 case series where 87.5 percent of knee pain patients improved on BPC 157 given alone or together with thymosin beta-4. Reported in the cited paper.
SourceA 2016 review of thymosin beta-4 reported faster dermal repair in chronic wounds, which is the component evidence behind the TB-500 half of this blend. Reported in the cited paper.
SourceInteractions
Questions
The directory
83 listed
Newsletter · Quarterly
Get notified about new lab results, price drops and supplier coupons before everyone else.
We respect your privacy. No spam.